Kornimate/medical-research-clean huggingface dataset:
immunohematology in covid-19 patients: a hospital-based retrospective cohort study

Conditions: Covid19

Summary: this is a hospital-based retrospective cohort study and the immunohematologic characteristics of covid-19 patients will be investigated systematically.

this is a hospital-based retrospective cohort study and the immunohematologic characteristics of covid-19 patients will be investigated systematically. in this study, we will seek to understand the association between sars-cov-2 infection and blood groups and explore the anti-a and anti-b effects in covid-19 patients with graded severity. we will analyze the transfusion requirement and the clinical recurrences of covid-19 patients. the discrepancy of blood group phenotypes in covid-19 patients with graded severity will be also analyzed on the molecular level. this retrospective cohort study was conducted using electronic health recording data in tongji hospital. the clinical characteristics for all eligible patients will be retrieved. the records will be verified to avoid possible bias. data collection was carried out independently by two investigators and reviewed by two different investigators.

Eligibility criteria:
inclusion criteria: * the patients who were diagnosed with covid-19 following the who interim guidelines (https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. 2020.) exclusion criteria: * male or female patients \<18 years of age

Keywords: immunohematology blood group covid-19
heart rate variability (hrv) to evaluate surgical risk on patients on beta blockers

Conditions: Cardiac Event Risk

Summary: beta blockers have been shown to decrease the risk of intraoperative cardiac events in patients at high cardiac risk. however, they have also been associated with side effects (for instance, stroke.) the role of beta blockers in patients at intermediate cardiac risk undergoing surgery is controversial. heart rate variability is a way of evaluating the cardiac function of a patient. decreased heart rate variability is associated with early cardiac death in patients with congestive heart failure (chf) and after a heart attack. it has been shown to transiently decrease in patients in hemorrhagic shock after trauma and returns to normal after resuscitation in trauma and burn patients. the investigators hypothesize that beta blockers will maintain pre operative heart rate variability in patients with intermediate risk of cardiac events during operative intervention with laparoscopic surgery.


Eligibility criteria:
inclusion criteria: * age 40-75 years old * intermediate risk of adverse cardiac events: * renal insufficiency (crcl \< 60) * diabetes mellitus * two of the following: * age \> 50 * obesity * hypertension * hyperlipidemia * hypercholesterolemia * prior stroke * undergoing an elective laparoscopic abdominal surgery less than three hours: * cholecystectomy * ventral hernia repair * umbilical hernia repair * gastric bypass or gastric banding exclusion criteria: * currently taking a beta blocker * prior heart attack * rhythm other than sinus on ecg * contraindication to beta blockers: * decompensated chf * severe valvular disease * asthma * copd * hypersensitivity to beta blockers * heart rate \< 60 * currently taking a calcium channel blocker * urgent or emergent surgery

Keywords: intermediate risk of adverse cardiac event undergoing laparoscopic surgical procedure age forty to seventy five
identification of heart failure patients by seismocardiography

Conditions: Heart Failure

Summary: the aim of the current study is to develop and validate an algorithm based on seismocardiography recordings to detect heart failure. echocardiography will be used as the golden standard for defining patients with heart failure.

seismocardiography is inspired from methods for the analysis of seismic activity and can be used to describe the heart's movements using a specially developed sensor placed on the patient's chest. the project aims to describe the motion of the heart using automated computer analysis of the seismocardiography signal for development of a simple method for the analysis of myocardial performance.

Eligibility criteria:
inclusion criteria: * male or female, aged 18 years or older * clinically suspected heart failure, and referred to an outpatient clinic * be able and willing to comply with the clinical investigational plan * have signed the informed consent form exclusion criteria: * known hf * known atrial fibrillation * acute coronary syndrome * implanted donor heart, mechanical heart, mechanical heart pump, pacemaker or cardioverter defibrillator (icd) * implanted electronic equipment in the area above and around the heart * significant operation scars, abnormal body shape, fragile or compromised skin in the seismocardiographic recording area (fourth left inter costal space and xiphoid process) * pregnancy extension study: inclusion criteria 1. male or female, aged 18 years or older 2. newly diagnosed hfref 3. be able and willing to comply with the clinical investigational plan 4. have signed the informed consent form exclusion criteria 1. known atrial fibrillation 2. acute coronary syndrome 3. implanted donor heart, mechanical heart, mechanical heart pump, pacemaker or cardioverter defibrillator (icd) 4. implanted electronic equipment in the area above and around the heart 5. significant operation scars, abnormal body shape, fragile or compromised skin in the seismocardiographic recording area (fourth left inter costal space and xiphoid process) 6. pregnancy

Keywords: seismocardiography
study on the interplay between twist1 and other emt regulators through microrna-29 family.

Conditions: Head-and-Neck Squamous Cell Carcinoma

Summary: investigation of the molecular mechanism and clinical significance of the interplay between twist1 and other emt regulators through microrna-29 family.

head and neck squamous cell carcinoma (hnscc) is one of the leading causes of cancer deaths worldwide, and it ranks the fourth male cancer-related death in taiwan. in hnscc, invasiveness and metastasis of cancer cells contribute to the major cause of mortality; therefore, elucidation of the mechanism and development of new strategies against metastasis is the utmost importance in treating advanced hnscc. epithelial-mesenchymal transition (emt) is a process by which epithelial cells lose their polarity and are converted to a mesenchymal phenotype, and recently is considered as the major mechanism for cancer metastasis. the initiation of emt is hallmarked by suppression of the intercellular junctional protein e-cadherin by a variety of transcriptional factors, including twist1, snail, slug, sip1, zeb1 and e47. however, during metastatic evolution, the interplay between different emt inducers has been investigated limitedly. previously study demonstrated that hypoxia induces emt of hnscc through induction of twist1 expression. additionally showed that twist1 promotes emt and tumor-initiating capability through upregulation of bmi1, and co-expression twist1 and bmi1 predicts a worse prognosis of hnscc cases. accumulated evidence suggests that micrornas play essential roles in cancer progression and metastasis. therefore, we aim to investigate the role of microrna in twist1-mediated cancer metastasis, and the interplay between twist1 and other emt regulators. our preliminary data showed that the expression of mir-29 family, including mir-29a, b, and c were increased in twist1-overexpressing hnscc cells. furthermore, we discovered that sin3a, a co-repressor of another emt regulator snail, is a target of mir-29s. we therefore speculate that twist1 modifies the function of snail through microrna machinery. in this proposal, we will delineate the regulatory mechanism of the twist1-mir29s-sin3a axis. we will also investigate the molecular interplay between twist1 and snail through twist1-mir29s-sin3a signal pathway. furthermore, we will elucidate the molecular basis and pathophysiologic significance of twist1-snail interaction under hypoxic environment. finally, we will confirm the in vitro finding by in vivo animal study and hnscc samples. these results will provide crucial information for understanding the molecular basis of hnscc metastasis, and will be valuable for developing new therapeutic strategies against advanced hnscc.

Eligibility criteria:
inclusion criteria: * head and neck cancer exclusion criteria: * pregnant woman

Keywords: head-and-neck squamous cell carcinoma (hnscc) epithelial-mesenchymal transition (emt) microrna29 twist1
pragmatic investigation of volume targeted ventilation-1

Conditions: Respiratory Failure; Acute Respiratory Distress Syndrome (ARDS); Ventilator Lung

Summary: this proposal will test the feasibility of implementing an assist volume control ventilation protocol in patients receiving mechanical ventilation in the medical intensive care unit. the trial will consist of a before-and-after trial design of block assignment to either adaptive pressure control (baseline) or assist volume control . this is a feasibility study looking at the management of patients in the ventilator.

over the course of 6 weeks, a before-and-after trial design of adaptive pressure control and assist volume control will be conducted. pre-trial planning phase: study protocols will be reviewed with key stakeholders (respiratory therapy providers and medical teams) weeks 1-2: data will be collected on our current adaptive pressure control ventilator protocol. week 3: the investigators will implement an assist volume control protocol. . patients already on mechanical ventilation will be converted to assist volume control; however, these patients will not be included in the primary analysis.in accordance with the consolidated framework for implementation research (cfir) approach, after 1 week of assist volume control the investigators will engage in quantitative and qualitative feedback with care providers to identify facilitators and barriers of assist volume control implementation. week 4-6: if the investigators identify substantial barriers, the investigators will pause and alter the protocol. if not, the investigators will continue assist volume control for an additional 2 weeks.

Eligibility criteria:
inclusion criteria: acute respiratory failure requiring mechanical ventilation medical intensive care unit admission exclusion criteria: chronic mechanical ventilation clinician use of non-volume-targeted ventilation as initial mode
comparison of double y-shaped plates and lag screws in fixation of anterior mandibular fractures

Conditions: Mandibular Fractures

Summary: this study is a prospective randomized controlled clinical trial. it was performed on sixteen patients with anterior mandibular fractures, to compare double y-shaped plates and lag screws in fracture fixation from clinical and radiographic perspectives.

this study is a prospective randomized controlled clinical trial. it was performed on sixteen patients with anterior mandibular fractures, selected from those admitted to the emergency department of alexandria university hospital. ethical approval for the study was obtained from the regional ethical review board of the faculty of dentistry, alexandria university. a written informed consent was signed by patients before the operation. patients were divided equally into two groups, each consisting of eight patients. assignment of each patient into one of either group was done using computer random numbers. group 1: underwent open reduction and internal fixation using two lag screws. group 2: underwent open reduction and internal fixation using double y-shaped plates.

Eligibility criteria:
inclusion criteria: * patients of both genders * with age ranging from 25 to 45 years, * suffering from anterior fractures of the mandible (symphyseal or parasymphyseal) exclusion criteria: * old fractures, * infected fractures * comminuted fractures
post-marketing safety study of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) mrna-1273 covid-19 vaccine in the united states

Conditions: SARS-CoV-2

Summary: the goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the sars-cov-2 mrna-1273 vaccine.

this retrospective observational cohort study will use secondary, de-identified individual-level medical and pharmacy claims data provided by healthverity.

Eligibility criteria:
inclusion criteria: * included in a health plan covered by healthverity database * covered by a health plan during at least 1 period of interest (pre-covid-19, active-covid-19, and post-eua periods), but not necessarily the full period. * demonstrate an aesi specified clean period of continuous baseline enrollment or activity before the period of interest (pre-covid-19, active-covid-19, and post-eua periods) during which the participant is covered. exclusion criteria: none

Keywords: mrna-1273 mrna-1273 vaccine sars-cov-2 sars-cov-2 vaccine coronavirus virus diseases messenger rna covid-19 covid-19 vaccine moderna
to evaluate the efficacy and safety of inhaled corticosteroids combined with bronchodilators and programmed death-ligand 1 (pd-l1) inhibitor plus platinum-based chemotherapy in patients with advanced lung squamous cell carcinoma complicated with chronic obstructive pulmonary disease (copd)

Conditions: Lung Cancer Squamous Cell; COPD

Summary: to evaluate the efficacy and safety of inhaled corticosteroids combined with bronchodilators and programmed death-ligand 1 (pd-l1) inhibitor plus platinum-based chemotherapy in patients with advanced lung squamous cell carcinoma complicated with chronic obstructive pulmonary disease (copd)


Eligibility criteria:
inclusion criteria: * this project is a multi-center, randomized controlled, intentionality analysis study. inclusion criteria: 1. age ≥18 years old; 2. histological or cytological examination confirmed clinically primary squamous non-small cell lung cancer stage iiib-iv (according to ajcc 8th edition); 3. patients with stable moderate to severe chronic obstructive pulmonary disease (copd) were diagnosed according to the gold2021 standard and the guidelines for diagnosis and treatment of chronic obstructive pulmonary disease (revised 2021), with blood eosinophils ≤300 /ul and ≥100 /ul; 4. the gene test showed that the driver gene (egfr/alk/braf/ros1/kras/ her2/met/ret /ntrk) was negative; 5. ecog ps 0-2 points; 6. clinical evaluation is suitable for suglizumab combined with paclitaxel (albumin-bound) and carboplatin anti-tumor first-line therapy, as well as chronic obstructive pulmonary maintenance therapy with long-acting bronchodilators or inhaled corticosteroids; 7. clinical records of suglizumab treatment, chemotherapy and other treatments are available; 8. patients who have previously used bronchodilators and inhaled corticosteroids should undergo a washout period of at least 15 days; 9. patients voluntarily join the project and sign informed consent; exclusion criteria: * 10. concurrent with any malignant active tumor other than squamous non-small cell lung cancer; 11. prior systematic treatment for advanced/metastatic non-small cell lung cancer; 12. patients with diseases requiring long-term oral or intravenous use of glucocorticoids, such as autoimmune diseases, asthma, nephritis, type 1 diabetes, hyperthyroidism, etc.; etc.; 13. oral or intravenous use of glucocorticoids for any reason within 1 month prior to screening; 14. the patient was assessed by the researchers as having severe liver and kidney dysfunction; 15. accompanied by acute type i/ii respiratory failure or long-term use of non-invasive or invasive ventilator assisted ventilation or frequent acute exacerbations (≥2 times/year of moderate and severe acute exacerbations); 16. women who are pregnant or nursing, or who are planning to become pregnant; currently receiving or planning to participate in any other clinical studies;
comprehensive genomic profiling combined with real life data of "the german-registry of incidental gallbladder carcinoma"

Conditions: Gallbladder Carcinoma

Summary: multicenter german- registry of incidental gallbladder carcinoma combining clinical real-world data and comprehensive genomic profiling. the registry collects medical data from clinical observation and molecular data derived from archival tumor tissue samples but does not define any medical intervention nor does it evaluate the efficacy or safety of the treatment decision made by the investigator.

in the largest cohort of igbc patients ever analysed in such a comprehensive approach * determine the course of patients in this rare kind of cancer * combine cgp analysis of histological tumor samples with clinical real-life data to get a comprehensive overview on igbc patients analysed and evaluate data to identify possible further (targeted) treatment possibilities * analyze potential risk factors associated with gallbladder carcinoma * assess the frequency of targetable mutations in igbc

Eligibility criteria:
inclusion criteria: histologically confirmed diagnosis of incidental gallbladder carcinoma * patient ≥ 18 years old * patient already deceased * available tumor tissue (ffpe block) exclusion criteria: patient under 18 years of age
use of 'mechanical power' as a predictor of increased serum and pulmonary proinflammatory cytokine concentrations in patients with acute hypoxemic respiratory failure: a prospective observational study

Conditions: Mechanical Power

Summary: the aim of this study is to report the proportion of patients with acute hypoxemic respiratory failyre (ahrf) undergoing mechanical ventilation who exceed 17 j/min of mechanical power (mp) and the difference in terms of proinflammatory cytokine concentration in blood samples and bronchoalveolar lavage. the main questions it aims to answer are: 1. which is the proportion of patients who exceed 17 j/min of mechanical power (mp) during the first 72 hours of mechanical ventilation? 2. is there a difference in terms of cytokine concentration in patients undergoing mechanical power \>17 j/min compared to \<17 j/min? patients will be divided into two groups based on respiratory mechanics measurements: low mp group (average mp \<17 j/min) and high mp group (average mp ≥17 j/min). the researchers will collect blood and bal samples and perform cytokine assays.


Eligibility criteria:
inclusion criteria: * patients with ahrf (p/f \<300 mmhg) undergoing invasive mechanical ventilation within 7 days from the onset of symptoms * invasive mechanical ventilation for less than 6 hours * evidence of newly developed lung consolidation on chest imaging (x-ray, ct) * age ≥18 years exclusion criteria: * prior invasive mechanical ventilation during the same hospitalization * tracheostomy * severe anemia (hb\<7g/dl) * severe neutropenia * renal insufficiency or rrt (renal replacement therapy) * noradrenaline \>0.5 mcg/kg/min * pregnancy * extracorporeal circulation (ecco2r, ecmo) * life expectancy \<24 hours as clinically judged * lack of consent
phase ii study of as1402 combined with letrozole to treat breast cancer

Conditions: Breast Carcinoma

Summary: the aim of this study is to compare the overall tumour response rate per recist in postmenopausal women with metastatic or locally advanced breast cancer receiving as1402 in combination with letrozole compared to letrozole alone


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed locally advanced or metastatic breast cancer not amenable to curative therapy * measurable disease according to the recist criteria * documented estrogen receptor-positive and/or progesterone receptor-positive tumour * postmenopausal women exclusion criteria: * prior chemotherapy and/or endocrine therapy for advanced breast disease * relapse within 12 months after treatment discontinuation of an aromatase inhibitor in the adjuvant setting * unknown hormonal receptor status * known her2/neu-positivity

Keywords: breast cancer
cd34+selection for partially matched family or matched unrelated adult donor transplant

Conditions: Leukemia; Lymphoma; Bone Marrow Failure; Immunodeficiencies; Histiocytosis; Sickle Cell Disease; Beta Thalassemia; Inborn Errors of Metabolism

Summary: cd34+ stem cell selection in children, adolescents and young adults receiving partially matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral blood stem cell transplant will be safe and well tolerated and be associated with a low incidence of serious (grade iii/iv) acute and chronic graft versus host disease (gvhd).

the selection of cd34+ cells is associated with the simultaneous depletion of t cells that are responsible for severe acute and chronic graft versus host disease (gvhd). successful engraftment is reported in adult patients with malignant and non-malignant disease who received cd34+ selected stem cells from hla-matched or mismatched mobilized peripheral blood (pbsc) or bone marrow. study design: selected patients defined in the eligibility criteria will enrolled on this study. patients will receive one of either full intensity or reduced intensity regimen based on the patient's disease status, organ function and performance and determined by the pi and will have peripheral blood undergo cd34 selection.

Eligibility criteria:
inclusion criteria: * adequate renal function defined as:serum creatinine \ 60 ml/min/m2 or an equivalent gfr as determined by the institutional normal range. * adequate liver function defined as:total bilirubin \<1.5 x normal, or sgot (ast) or sgpt (alt) \<3.0 x normal * adequate cardiac function defined as:shortening fraction \>27% by echocardiogram, or ejection fraction of \>47% by radionucleotide angiogram or echocardiogram. * adequate pulmonary function defined as:uncorrected dlco \>50% by pulmonary function test. for children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \>94% on room air. eligibility for reduced intensity regimen: * adequate renal function defined as:serum creatinine 2.0 x normal, or creatinine clearance or radioisotope gfr \> 40 ml/min/m2 or an equivalent gfr as determined by the institutional normal range. * adequate liver function defined as:total bilirubin \< 2.5 x normal; or sgot (ast) or sgpt (alt) \< 5.0 x normal. * adequate cardiac function defined as:shortening fraction of \>25% by echocardiogram, or ejection fraction of \>40% by radionuclide angiogram or echocardiogram. * adequate pulmonary function defined as:dlco \>35% by pulmonary function test. for children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \>94% in room air. exclusion criteria: * pregnancy/breast feeding: females who are pregnant or breast-feeding are not eligible. * infection: patients with documented uncontrolled infection at the time of study entry are not eligible.

Keywords: unrelated donor transplant cd34 selection